Zepbound (Tirzepatide) Shortage Guide for Healthcare Providers

The Zepbound shortage has created real clinical headaches for prescribers across the US — from prior authorization tangles to patients who can't find their dose in stock. This guide gives you a practical framework for managing tirzepatide shortages in your practice: how to navigate therapeutic alternatives, switch patients safely, set expectations clearly, and use tools like FindUrMeds to reduce the administrative burden on your team.

---

Understanding the Current Zepbound Shortage Landscape

Zepbound (tirzepatide injection) received FDA approval for chronic weight management in November 2023, and demand quickly outpaced supply. The FDA added tirzepatide to its official drug shortage list, and while availability has improved in some markets and dose strengths, shortages remain inconsistent — particularly for mid- and higher-dose vials (7.5 mg, 10 mg, 12.5 mg, and 15 mg).

A few factors are driving continued supply pressure:

• Explosive demand. The GLP-1/GIP class has seen unprecedented uptake. Prescriptions for Zepbound and Mounjaro (the diabetes-indicated formulation of tirzepatide) surged well beyond initial supply projections.
• Dose-specific bottlenecks. Starter doses (2.5 mg and 5 mg) are generally more available. Patients titrating upward often hit walls at higher dose strengths.
• Pharmacy-level variability. Even when national supply improves, distribution is uneven. One Walgreens may have 10 mg in stock while a CVS three miles away has nothing. This creates a frustrating patchwork that strains your staff and your patients.
• Compounding market disruption. The FDA's February 2025 removal of tirzepatide from the shortage list triggered enforcement action against compounding pharmacies producing unauthorized copies. This has closed off an alternative some patients were using, pushing more demand back to brand-name supply channels.

The practical takeaway: supply is recovering but not resolved. Your patients need proactive guidance, and your practice needs a reliable workflow.

---

Therapeutic Alternatives and Switching Protocols

When Zepbound is unavailable, you have a few legitimate clinical pathways. None of them are perfect substitutes, but each has a role depending on your patient's profile.

Option 1: Mounjaro (Tirzepatide for Type 2 Diabetes)

This is the same molecule — tirzepatide — just indicated for glycemic control rather than weight management. For patients with comorbid type 2 diabetes, switching to Mounjaro may be appropriate and is often more straightforward from an insurance standpoint. For patients without a diabetes diagnosis, off-label prescribing of Mounjaro for obesity is possible but creates payer friction; expect prior authorization pushback.

Switching protocol: Dose-for-dose conversion. If a patient is stable on Zepbound 7.5 mg weekly, prescribe Mounjaro 7.5 mg weekly. No titration adjustment needed if the switch is seamless and within the same dose range.

Option 2: Semaglutide-Based Agents (Wegovy or Ozempic)

Semaglutide is a GLP-1 receptor agonist, not a dual GIP/GLP-1 agonist like tirzepatide. Clinically, tirzepatide tends to produce greater weight loss on average, but semaglutide is a well-established, effective option for many patients.

Key clinical considerations when switching:

• There is no validated equivalent-dose conversion between tirzepatide and semaglutide. Most clinicians recommend restarting at a low semaglutide dose (0.25 mg weekly for Wegovy) and re-titrating to minimize GI side effects.
• Patients who achieved significant appetite suppression on tirzepatide may notice a difference in satiety signaling on semaglutide, given the loss of GIP receptor activity.
• Patients should be counseled that some weight may be regained during the transition period, particularly if there's a gap in therapy. This is not a treatment failure — it reflects the medications' mechanisms.

Switching protocol: Discontinue tirzepatide. Begin semaglutide at 0.25 mg subcutaneous weekly. Titrate per standard Wegovy protocol (every 4 weeks). Monitor for GI tolerance and weight response over the first 12 weeks.

Option 3: Holding Therapy Temporarily

For patients who are clinically stable, well-established on their weight loss journey, and facing a short-term shortage, a brief hold of 2–4 weeks may be reasonable. Counsel patients that appetite may return and weight regain is possible; encourage continued behavioral strategies. This should not be a default — it should be a deliberate, communicated clinical decision.

Option 4: Older Anti-Obesity Agents

Phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), or orlistat may bridge some patients, particularly those who are unable to access any injectable GLP-1/GIP therapy. These agents have more modest efficacy profiles and different side effect considerations. Document your rationale carefully, especially if insurance is involved.

---

Prior Authorization Considerations During Shortages

PA requirements don't disappear during shortages — in some cases, they become more complicated. A few things to keep in mind:

Switching diagnoses. If you're considering Mounjaro for a non-diabetic patient as a Zepbound substitute, be prepared for denial. Most payers require a type 2 diabetes diagnosis for Mounjaro coverage. Document the shortage and clinical necessity clearly in your appeal letters.

Step therapy requirements. Some plans require documented failure on other weight loss interventions before approving Zepbound or Wegovy. If your patient has already met step therapy requirements for Zepbound, you may need to re-establish that history when requesting Wegovy. Attach prior approval letters where possible.

Shortage documentation. Include FDA shortage status in PA appeals when relevant. Reference the FDA Drug Shortages database. Some payers have expedited review processes for shortage-related switches; it's worth calling the PA line to ask.

Time-limited approvals. If a patient's Zepbound PA lapses during a shortage because they couldn't fill the prescription in time, proactively contact the payer to request an extension before it expires. Restarting the PA process from scratch is unnecessarily burdensome for everyone.

---

Communicating With Patients About Shortages

How you frame a shortage conversation matters. Patients who feel informed and supported stay engaged in their treatment. Patients who feel dismissed — or who find out from the pharmacy instead of from you — lose trust.

Be proactive. If your practice is aware of supply issues with a particular dose strength, flag it before patients call in a panic at the pharmacy. A quick message through your patient portal goes a long way.

Validate the frustration. These medications are expensive, often only partially covered by insurance, and patients have invested real effort in their treatment. Losing access mid-titration is genuinely disruptive. Acknowledge that.

Explain the mechanism. Briefly explain why GLP-1/GIP therapy can't just be stopped cold: appetite typically returns, and weight regain can begin quickly. This helps patients understand why finding their medication matters — and motivates them to be proactive about locating stock.

Give them actionable steps. Don't leave patients to navigate the shortage alone. Direct them to resources — including services like FindUrMeds — that can search across pharmacies on their behalf. how to help patients find Zepbound in stock

Discuss cost backup plans. If insurance issues compound the supply problem, patients should know what their options are. Eli Lilly's savings programs and alternative pricing resources can help bridge gaps. how to help patients save money on Zepbound

---

Using FindUrMeds as a Provider Resource

Your staff shouldn't be spending hours calling pharmacies to locate tirzepatide. That's not a good use of clinical time — and it rarely works, because pharmacy inventory changes hourly.

FindUrMeds is built for exactly this situation. The service contacts pharmacies directly across a network of 15,000+ locations — including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — and locates in-stock prescriptions within 24–48 hours. The 92% success rate reflects a genuine ability to find medications even when patients have already exhausted their usual options.

How to integrate FindUrMeds into your workflow:

• Add it to your shortage resource sheet or patient handout for GLP-1 medications.
• When writing a Zepbound prescription, mention FindUrMeds in your patient instructions if supply is tight in your area.
• For practices managing large panels of GLP-1 patients, designate a staff member to refer shortage cases to FindUrMeds systematically rather than handling calls ad hoc.
• Trusted by 200+ healthcare providers, FindUrMeds has experience working within the prescriber-patient relationship and understands the urgency of medication continuity.

Referring patients to FindUrMeds is not a workaround — it's a legitimate, practical solution to a real supply chain problem.

---

Clinical Considerations When Switching or Interrupting Therapy

A few clinical notes worth keeping top of mind:

Weight regain is expected and reversible. Patients who interrupt tirzepatide therapy typically experience some weight regain. Studies show that weight recidivism begins within weeks of stopping GLP-1/GIP therapy. Reinforce that this reflects the medication's mechanism — not patient failure — and that weight loss tends to resume when therapy restarts.

GI tolerability may reset. When patients restart tirzepatide or switch to semaglutide after a gap, GI side effects (nausea, diarrhea) may return even if they had previously resolved. Re-titrate accordingly.

Monitor metabolic parameters at transitions. If a patient has comorbid type 2 diabetes or prediabetes, a gap in GLP-1/GIP therapy may affect glycemic control. Check HbA1c and fasting glucose at follow-up and adjust any concomitant glucose-lowering medications as needed.

Document clinical decision-making. Any shortage-related switch or hold should be clearly documented in the medical record — your rationale, the supply situation, the alternatives considered, and the plan for returning to original therapy when available.

---

FAQ for Prescribers

Can I prescribe Mounjaro off-label for weight loss during a Zepbound shortage?

Yes, off-label prescribing of Mounjaro for obesity is legally permissible. However, insurance coverage is unlikely for patients without a type 2 diabetes diagnosis, and out-of-pocket costs can be significant. Weigh this carefully with your patient and document your rationale.

How long can patients safely interrupt Zepbound therapy before it affects their outcomes?

There's no hard clinical threshold, but data from the SURMOUNT-4 trial suggest that weight regain begins relatively quickly after discontinuation — most patients regain a meaningful portion of lost weight within a year. Short interruptions (2–4 weeks) are generally manageable with behavioral support; longer gaps warrant therapeutic alternatives.

Should I restart titration after a shortage gap?

It depends on the length of the gap and the patient's tolerability history. After a gap of more than 4 weeks, most clinicians recommend dropping back one dose level to minimize GI side effects, then re-titrating. After shorter gaps, resuming at the current dose is often reasonable with close monitoring.

Is there any shortage documentation I should provide to insurers when requesting PA for an alternative?

Yes. Reference the FDA Drug Shortages database listing for tirzepatide and include it in your PA appeal documentation. Note the date, the patient's current dose strength, and the documented unavailability at local pharmacies. Some payers have shortage-specific PA pathways — it's worth asking your payer contact or provider relations line directly.

---

Need help finding Zepbound in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Zepbound Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →